

Ref. No: 2520  
Date: 22<sup>nd</sup> April 2026  
Subject: Treatment with immunology medicines

## REQUEST & RESPONSE

Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1<sup>st</sup> Jan 2026 and 31<sup>st</sup> March 2026, or the latest 3-month period for which you have data?

Drug Name	Total number of patients treated <b>regardless of diagnosis</b>
Adalimumab	787
Etrasimod	0
Filgotinib	27
Golimumab	43
Guselkumab	45
Infliximab (Biosimilars)	325
Infliximab (Remicade)	<5
Mirikizumab	16
Ozanimod	<5
Risankizumab	52
Tofacitinib	44
Upadacitinib	95
Ustekinumab	227
Vedolizumab	110

Q2. How many patients were treated by the Gastroenterology Department or Clinic with the following drugs between 1<sup>st</sup> Jan 2026 and 31<sup>st</sup> March 2026, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <b>Gastroenterology Department</b>
Adalimumab	153
Etrasimod	0

Filgotinib	11
Golimumab	<5
Guselkumab	0
Infliximab (Biosimilars)	295
Infliximab (Remicade)	<5
Mirikizumab	15
Ozanimod	<5
Risankizumab	25
Tofacitinib	14
Upadacitinib	46
Ustekinumab	179
Vedolizumab	110

Q3. How many patients with Crohn's Disease or Ulcerative Colitis, in total regardless of department / clinic, were treated with the following drugs between 1<sup>st</sup> Jan 2026 and 31<sup>st</sup> March 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with	Number patients with
	<b><u>Crohn's Disease</u></b>	<b><u>Ulcerative Colitis</u></b>
Adalimumab	22	17
Etrasimod	0	0
Filgotinib	0	0
Golimumab	0	1
Guselkumab	0	0
Infliximab (Biosimilars)	41	24
Infliximab (Remicade)	0	0
Mirikizumab	<5	2
Ozanimod	0	0
Risankizumab	9	1
Tofacitinib	0	1
Upadacitinib	6	7
Ustekinumab	29	6
Vedolizumab	18	39